Who is a candidate for eculizumab treatment for aHUS?

Mar 21, 2025 ... Eculizumab Biosimilars in PNH: Working Towards Broader Patient Access ... Eculizumab was the first drug approved for the treatment of complement- ... This medication helps to block the decrease in red blood cells and can improve the symptoms of anemia (such as tiredness, shortness of breath) and decrease the ... Aug 16, 2024 ... How Much Does Soliris Cost? Cost can vary depending on your insurance plan, location, and pharmacy. Contact your insurance provider to determine ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ... Feb 7, 2019 ... Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study Aug 15, 2018 ... Reported relapse rates in aHUS after stopping eculizumab are as high as 30%, suggesting indefinite therapy is reasonable and that patients who choose to stop ... This medication is given by a healthcare provider as an infusion through the vein to stop the body's immune system from attacking itself. Soliris (eculizumab) ... Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). MEDICATION GUIDE. SOLIRIS® (so-leer-is). (eculizumab) injection, for intravenous use. What is the most important information I should know about SOLIRIS?